AstraZeneca FluMist Supply Jumps With CDC's Seal Of Approval
US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.
You may also be interested in...
US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.
Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.
Agencies seek public comment on how they can modernize merger guidelines to enforce antitrust laws. List of questions, including what types of evidence show that a merger could reduce competition, indicate pharma and other mergers will face greater scrutiny.